ClinicalTrials.gg
CompletedNCT06109818Updated Feb 28, 2025

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of ICP-488 Tablets and ICP-488 Placebo in Moderate to Severe Plaque Psoriasis, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Completed at 31 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
109th of 182
129 · median 171
Started
2024
with 24 others
Phase 2
42 of 206
11 open now
Registered
118th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 109th largest by enrollment of the 182 interventional ones that give a count, is one of 25 that started in 2024, is one of 42 in phase 2, and was the 118th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate ICP-488.Efficacy, safety, PK, and PD characteristics in Chinese adults with moderate to severe plaque psoriasis.

03

Conditions studied

  • Moderate to Severe Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily participate in this study and have signed .
  2. Male or female subjects between the ages of 18 and 70 (including the threshold) at the time of signing the ICF.
  3. History of plaque psoriasis ≥6 months at baseline.
  4. Subjects need to receive systemic therapy and/or phototherapy.
  5. The following three criteria were met: a) psoriasis Area and Severity index (PASI) score ≥12; b) Psoriasis affected body surface area (BSA) ≥10%; c) Static physician overall assessment (sPGA) ≥3 scores

Exclusion criteria

Exclusion Criteria:

  1. The diagnosis was non-plaque psoriasis.
  2. Presence of infection or immune-related disease.
  3. Subjects with a history of TB or at risk for TB.
  4. Received related treatment within the time window specified in the protocol.
  5. An interval of less than 5 half-lives or 28 days (if any available halflife data) from the last dose of a strong CYP1A2 inhibitor or inducer, or a plan to use concurrently medications, dietary supplements or food with strong CYP1A2 inhibitory or inductive effect during study participation.
  6. The investigator has determined that there are test results and that participation in this trial would pose an unacceptable risk to patients; Or the laboratory values of the subjects in the screening period meet the criteria specified in the protocol.
  7. Pregnant or lactating women, or women who plan to become pregnant during study participation.
  8. A history of severe drug allergies.
  9. Any other conditions in which the investigator considers it unsuitable for the subject to participate in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    ICP-488 low dose

    Drug: ICP-488 Tablets · Drug: ICP-488 Placebo

  • Experimental
    ICP-488 high dose

    Drug: ICP-488 Tablets

  • Placebo comparator
    Placebo

    Drug: ICP-488 Placebo

Interventions

  • ICP-488 will be administered as tablet

  • DrugICP-488 Placebo

    ICP-488 Placebo will be administered as tablet

06

What researchers measure

Primary outcomes

  1. Percentage of subjects who achieved a PASI 75 response (a reduction of minimum 75% from baseline in PASI score) at Week 12.

    Proportion of subjects who achieved PASI 75 (PASI score improvement of at least 75% from baseline) at week 12.

    Time frame: Baseline up to Week 12

07

Study locations

31 sites
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100000, China
  • China-Japan Friendship Hospital
    Beijing, Beijing 100000, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400000, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350000, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong 510000, China
  • Guangdong Hospital of Traditional Chinese Medicine
    Guangzhou, Guangdong 510120, China
  • Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou 550081, China
  • The Affiliated Hospital of Chengde Medical College
    Chengde, Hebei 067032, China
  • The first hospital of hebei medical university
    Shijia Zhuang, Hebei 050000, China
  • The Second Affiliated Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
  • Nanyang city first People's Hospital
    Nanyang, Henan 473000, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450000, China
  • Shiyan City People's Hospital
    Shiyan, Hubei 442000, China
  • Wuhan University People's Hospital
    Wuhan, Hubei 430000, China
  • Wuhan No.1 hospital
    Wuhan, Hubei 430030, China
  • Xiangya hospital central south university
    Changsha, Hunan 410008, China
  • Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia Autonomous Region 010000, China
  • Changzhou First People's Hospital
    Changzhou, Jiangsu 213000, China
  • Lianyungang First People's Hospital
    Lianyungang, Jiangsu 222000, China
  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of medical Sciences, Peking Union Medical College
    Nanjing, Jiangsu 210042, China
  • First Hospital of Jilin University
    Changchun, Jilin 130000, China
  • Mei he kou central hospital
    Meihekou, Jilin 135099, China
  • Central Hospital affiliated to shandong first medical unversity
    Jinan, Shandong 250013, China
  • Shanghai Dermatology Hospital
    Shanghai, Shanghai 200000, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai 200040, China
  • Chengdu Second People's Hospital
    Chengdu, Sichuan 610000, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650000, China
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang 310000, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang 310000, China
  • The First Hospital of Jiaxing
    Jiaxing, Zhejiang 314000, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Aug 2024, 7 months.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 7 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2023
First posted
Oct 31, 2023
StartActual
Jan 4, 2024
Primary completionActual
Aug 5, 2024
CompletionActual
Sep 18, 2024
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06109818
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Jan 4, 2024
Primary completion
Aug 5, 2024
Completion
Sep 18, 2024
Last update
Feb 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ICP-488

Start the discussion